vs

Side-by-side financial comparison of Hudson Pacific Properties, Inc. (HPP) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Hudson Pacific Properties, Inc. is the larger business by last-quarter revenue ($256.0M vs $207.3M, roughly 1.2× Ultragenyx Pharmaceutical Inc.). Ultragenyx Pharmaceutical Inc. runs the higher net margin — -62.0% vs -109.4%, a 47.4% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 22.1%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 9.4%).

Hudson Pacific Properties is a real estate investment trust with 15.8 million square feet of office buildings, 1.5 million square feet of sound stages, and undeveloped rights for 3 million square feet of additional commercial property. Its properties are on the West Coast of the United States and Vancouver. It is organized in Maryland and headquartered in Los Angeles. It is the largest independent operator of sound stages in Los Angeles.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

HPP vs RARE — Head-to-Head

Bigger by revenue
HPP
HPP
1.2× larger
HPP
$256.0M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+3.8% gap
RARE
25.9%
22.1%
HPP
Higher net margin
RARE
RARE
47.4% more per $
RARE
-62.0%
-109.4%
HPP
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
9.4%
HPP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HPP
HPP
RARE
RARE
Revenue
$256.0M
$207.3M
Net Profit
$-280.2M
$-128.6M
Gross Margin
60.0%
Operating Margin
-109.8%
-54.7%
Net Margin
-109.4%
-62.0%
Revenue YoY
22.1%
25.9%
Net Profit YoY
-61.5%
3.5%
EPS (diluted)
$-11.57
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HPP
HPP
RARE
RARE
Q4 25
$256.0M
$207.3M
Q3 25
$186.6M
$159.9M
Q2 25
$190.0M
$166.5M
Q1 25
$198.5M
$139.3M
Q4 24
$209.7M
$164.6M
Q3 24
$200.4M
$139.5M
Q2 24
$218.0M
$147.0M
Q1 24
$214.0M
$108.8M
Net Profit
HPP
HPP
RARE
RARE
Q4 25
$-280.2M
$-128.6M
Q3 25
$-144.1M
$-180.4M
Q2 25
$-87.8M
$-115.0M
Q1 25
$-80.3M
$-151.1M
Q4 24
$-173.5M
$-133.2M
Q3 24
$-107.0M
$-133.5M
Q2 24
$-47.6M
$-131.6M
Q1 24
$-53.4M
$-170.7M
Gross Margin
HPP
HPP
RARE
RARE
Q4 25
60.0%
Q3 25
44.3%
Q2 25
43.1%
Q1 25
42.9%
Q4 24
44.7%
Q3 24
42.7%
Q2 24
48.0%
Q1 24
48.6%
Operating Margin
HPP
HPP
RARE
RARE
Q4 25
-109.8%
-54.7%
Q3 25
-77.2%
-106.9%
Q2 25
-46.0%
-64.8%
Q1 25
-40.4%
-102.6%
Q4 24
-83.2%
-74.3%
Q3 24
-52.3%
-94.6%
Q2 24
-21.6%
-79.1%
Q1 24
-24.9%
-151.9%
Net Margin
HPP
HPP
RARE
RARE
Q4 25
-109.4%
-62.0%
Q3 25
-77.2%
-112.8%
Q2 25
-46.2%
-69.0%
Q1 25
-40.5%
-108.5%
Q4 24
-82.7%
-80.9%
Q3 24
-53.4%
-95.7%
Q2 24
-21.8%
-89.5%
Q1 24
-24.9%
-156.8%
EPS (diluted)
HPP
HPP
RARE
RARE
Q4 25
$-11.57
$-1.28
Q3 25
$-0.30
$-1.81
Q2 25
$-0.41
$-1.17
Q1 25
$-0.53
$-1.57
Q4 24
$-1.19
$-1.34
Q3 24
$-0.69
$-1.40
Q2 24
$-0.33
$-1.52
Q1 24
$-0.37
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HPP
HPP
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$138.4M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$3.0B
$-80.0M
Total Assets
$7.3B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HPP
HPP
RARE
RARE
Q4 25
$138.4M
$421.0M
Q3 25
$190.4M
$202.5M
Q2 25
$236.0M
$176.3M
Q1 25
$86.5M
$127.1M
Q4 24
$63.3M
$174.0M
Q3 24
$90.7M
$150.6M
Q2 24
$78.5M
$480.7M
Q1 24
$114.3M
$112.3M
Stockholders' Equity
HPP
HPP
RARE
RARE
Q4 25
$3.0B
$-80.0M
Q3 25
$3.2B
$9.2M
Q2 25
$3.4B
$151.3M
Q1 25
$2.8B
$144.2M
Q4 24
$2.9B
$255.0M
Q3 24
$3.0B
$346.8M
Q2 24
$3.1B
$432.4M
Q1 24
$3.2B
$140.3M
Total Assets
HPP
HPP
RARE
RARE
Q4 25
$7.3B
$1.5B
Q3 25
$7.8B
$1.2B
Q2 25
$8.1B
$1.3B
Q1 25
$8.0B
$1.3B
Q4 24
$8.1B
$1.5B
Q3 24
$8.3B
$1.5B
Q2 24
$8.4B
$1.6B
Q1 24
$8.3B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HPP
HPP
RARE
RARE
Operating Cash FlowLast quarter
$121.0M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HPP
HPP
RARE
RARE
Q4 25
$121.0M
$-99.8M
Q3 25
$33.2M
$-91.4M
Q2 25
$-2.0M
$-108.3M
Q1 25
$30.5M
$-166.5M
Q4 24
$164.7M
$-79.3M
Q3 24
$63.7M
$-67.0M
Q2 24
$35.6M
$-77.0M
Q1 24
$65.1M
$-190.7M
Free Cash Flow
HPP
HPP
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
HPP
HPP
RARE
RARE
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
HPP
HPP
RARE
RARE
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Q1 24
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HPP
HPP

Core Office$217.1M85%
Studio Segment$21.8M9%
Ancillary Revenue$20.2M8%
Chargebacks$3.3M1%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons